financetom
Business
financetom
/
Business
/
Macrotech Developers Q1 profit falls 34%, sales booking jumps to record Rs 3,350 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Macrotech Developers Q1 profit falls 34%, sales booking jumps to record Rs 3,350 crore
Jul 27, 2023 2:57 PM

Realty firm Macrotech Developers on Thursday reported a 34 percent decline in its consolidated net profit to Rs 179.2 crore for the June 2023 quarter on lower income.

Share Market Live

NSE

Its net profit stood at Rs 271.3 crore in the year-ago period.

The total income fell to Rs 1,671.8 crore in the April-June quarter of 2023-24 from Rs 2,675.8 crore in the corresponding period of the previous year, said Macrotech Developers in a regulatory filing.

Macrotech Developers, which sells its properties under the Lodha brand, has a major presence in Mumbai Metropolitan Region (MMR) and Pune markets. It has also forayed into the Bengaluru market.

Commenting on the performance, Abhishek Lodha, MD & CEO, Macrotech Developers Ltd, said, "Q1 FY24 has turned out to be our best ever 1st quarter pre-sales performance. Our pre-sales for the quarter at Rs 3,350 crore grew by 17 per cent”. ”This reinforces our belief in the sustainable nature of the strong housing demand. With the likelihood of a downward journey of interest rates in the next few quarters after witnessing a pause by the RBI, we see momentum for housing continuing to strengthen," Lodha said.

He said the company has a "burgeoning pipeline" of new business development opportunities on the back of our strong brand and proven ability to quickly monetise any land asset, making landowners prefer Lodha.

"We added five new projects with GDV (gross development value) potential of Rs 12000 crore in Q1FY24. The new projects include projects in the Western Suburbs of MMR (Mumbai Metropolitan Region), Bengaluru and in Alibaug," Lodha said.

Macrotech Developers has delivered more than 95 million square feet of real estate and is currently developing over 110 million square feet under its ongoing and planned portfolio.

The Group has about 4,300 acres of land beyond its ongoing and planned portfolio, which will be utilised in developing further residential, commercial and industrial & logistics spaces.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Southwest Airlines Raises Q4 Revenue Guidance Amid Strong Leisure Travel Demand
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Southwest Airlines ( LUV ) said in a regulatory filing Thursday that it increased its Q4 unit revenue growth forecast to a range of 5.5% to 7% from the previous range of 3.5% to 5.5%, citing better-than-expected leisure travel demand and revenue optimization efforts. The carrier said it now expects Q4 capacity to...
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Patterson Companies Fiscal Q2 Adjusted Earnings Down, Sales Rise; Lowers Fiscal 2025 Adjusted EPS Guidance
Dec 5, 2024
07:45 AM EST, 12/05/2024 (MT Newswires) -- Patterson Companies ( PDCO ) reported fiscal Q2 adjusted earnings Thursday of $0.47 per diluted share, down from $0.50 a year earlier. A single analyst polled by FactSet expected $0.47. Net sales for the fiscal quarter ended Oct. 26 was $1.67 billion, up from $1.65 billion a year earlier. Analysts surveyed by FactSet...
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Merck Begins Late-Stage Trial to Evaluate Lagevrio for Treatment of COVID-19 in High-Risk Adults
Dec 5, 2024
07:47 AM EST, 12/05/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that it has started a late-stage clinical trial to assess investigational oral antiviral COVID-19 medicines Lagevrio or molnupiravir for the treatment of adults with COVID-19 who are at high risk for disease progression. Lagevrio is being developed by Merck ( MRK ) in collaboration with Ridgeback Biotherapeutics....
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
CME Group Board Approves $3 Billion Stock Buyback Plan, $2.10 Billion Annual Variable Dividend
Dec 5, 2024
07:50 AM EST, 12/05/2024 (MT Newswires) -- CME Group ( CME ) said Thursday its board approved an annual variable dividend totaling $2.10 billion as well as a share repurchase program of up to $3 billion of Class A common stock. The dividend amounts to $5.80 per share and is payable Jan. 16, 2025, to shareholders of record as of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved